Alain R Baulard Selected Research

Ethionamide (Trecator-SC)

3/2024	Crystal structure of the Mycobacterium tuberculosis VirS regulator reveals its interaction with the lead compound SMARt751.
1/2022	The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.
1/2020	Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
1/2019	A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR.
11/2018	Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
12/2017	New active leads for tuberculosis booster drugs by structure-based drug discovery.
3/2017	Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
5/2014	Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands.
11/2013	Structural and docking studies of potent ethionamide boosters.
4/2012	Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alain R Baulard Research Topics

Disease

18	Tuberculosis (Tuberculoses) 03/2024 - 12/2003
2	Infections 01/2020 - 03/2017
1	Extensively Drug-Resistant Tuberculosis 11/2013
1	Bacterial Infections (Bacterial Infection) 05/2012
1	Acquired Immunodeficiency Syndrome (AIDS) 05/2012
1	Coinfection 05/2012
1	Pulmonary Tuberculosis 01/2007
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 10/2006

Drug/Important Bio-Agent (IBA)

12	Ethionamide (Trecator-SC)FDA Link 03/2024 - 03/2006
4	ProdrugsIBA 03/2024 - 12/2017
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2004
3	LigandsIBA 03/2024 - 10/2004
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 11/2018
2	ImmunosorbentsIBA 01/2007 - 07/2004
2	EnzymesIBA 01/2007 - 07/2004
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 02/2023
1	Mixed Function Oxygenases (Monooxygenases)IBA 01/2022
1	OxadiazolesIBA 01/2020
1	CyclodextrinsIBA 01/2019
1	SMARt-420IBA 03/2017
1	Linezolid (Zyvox)FDA Link 05/2012
1	Metronidazole (Metric)FDA LinkGeneric 05/2012
1	Antitubercular AgentsIBA 05/2012
1	Gatifloxacin (Zymar)FDA Link 05/2012
1	Moxifloxacin (Avelox)FDA Link 05/2012
1	DNA (Deoxyribonucleic Acid)IBA 04/2012
1	Immunoglobulin G (IgG)IBA 01/2007
1	Immunoglobulin M (IgM)IBA 01/2007
1	Immunoglobulin A (IgA)IBA 01/2007
1	Mycolic Acids (Mycolic Acid)IBA 12/2003

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 11/2018
1	Therapeutics 05/2009